Respiratory Tract DiseasesNCT07780331
The Effect of Using Virtual Reality Glasses and Gaming Cards on Fear, Anxiety, and Physiological Parameters in Children Administered Inhaler Medication
A study testing Virtual Reality Goggles (VR BOX), Interactive Distraction Cards (DistrACTION® Cards) and Standard Clinical Care in people with Respiratory Tract Diseases and Pediatric Disorders, run by Bandırma Onyedi Eylül University at 1 site in Turkey (Türkiye).
Trial summary
This study aims to evaluate the effects of using virtual reality headsets and play cards during the administration of inhaler medication in pediatric patients. The primary goal is to determine how these distraction methods influence children's fear, anxiety levels, and physiological parameters (such as heart rate and… Read more about this study
- Who is it for?
- Ages 4 to 6 yearsHealthy volunteers can take part
- Conditions the study is for
- Respiratory Tract Diseases, Pediatric Disorders, Anxiety
- What is being tested?
- Virtual Reality Goggles (VR BOX), Interactive Distraction Cards (DistrACTION® Cards) and Standard Clinical Care
- Type of treatment
- Medical device, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 28 Sep 2025to Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 4 to 6 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Child being between the ages of 4 and 6 years.
- Parents and children being completely voluntary to participate in the study.
- Child having no visual, auditory, or cognitive communication barriers.
- Child's cognitive level and motor development being appropriate for their age.
- Child having no life-threatening acute or chronic systemic disease.
- Child having no mental or neurological disability or condition.
- Child and parent being fully open to effective communication and clinical cooperation.
- Child having no medical condition that prevents inhaler mask or nebulizer application.
Who cannot join
- Child having any acute clinical condition that mechanically prevents inhaler treatment.
- Child having a severe, life-threatening acute or chronic health problem at presentation.
- Sudden development of severe clinical instability preventing completion of the trial.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Diler Yılmaz, Prof. Dr. contact
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Susurluk State Hospital, Emergency Department
Balıkesir, Balıkesir, 10600
Ecem Bakış, BSc, RN, +90 545 935 50 68, bakisecem0@gmail.com
Diler Yılmaz, Prof. Dr., daydin@bandirma.edu.tr
About this study
This study aims to evaluate the effects of using virtual reality headsets and play cards during the administration of inhaler medication in pediatric patients. The primary goal is to determine how these distraction methods influence children's fear, anxiety levels, and physiological parameters (such as heart rate and oxygen saturation). The study population consists of pediatric patients aged between 4 and 6 years. Data collection for the targeted sample size of 150 children commenced in September, and the recruitment process is currently ongoing.Children receiving inhaler treatments often experience fear and anxiety, which can negatively affect their treatment compliance and vital signs. In this study, participants are divided into different groups to compare the effectiveness of virtual reality headsets and traditional play cards as distraction tools.
Read the detailed description
This single-blind, parallel-group, randomized controlled clinical trial is designed to evaluate and compare the efficacy of two distinct cognitive distraction techniques, namely virtual reality goggles and interactive distraction cards, against a standard care control group on fear, anxiety, and vital physiological parameters in pediatric patients aged four to six years requiring inhaler medication within an emergency department setting. The study is actively being conducted at the Emergency Department of Susurluk State Hospital, having commenced in September 2025. The target sample size was rigorously calculated using G*Power software based on a standard effect size of 0.25, a significance level of 0.05, and a statistical power of 0.90 for a mixed-design repeated measures analysis of variance, determining a minimum required sample size of 45 participants per group. To account for potential data loss or attrition during the ongoing clinical process, the sample size was increased by approximately ten percent, aiming to recruit a total of 150 pediatric patients equally distributed with 50 participants in each of the three study arms.
To eliminate selection bias and ensure an equal distribution of demographic factors, a stratified block randomization method based on gender is utilized. An online randomizer program is managed by an independent faculty member not involved in the research team to generate two separate randomization sequences for female and male children with variable block sizes of three and six to ensure balanced allocations across the arms. Sequential protocol numbers corresponding to the gender-specific lists are kept completely concealed from the primary researcher until immediately prior to the clinical intervention. While researcher blinding is impossible due to the nature of administering the interventions, a strict single-blind protocol is maintained for data analysis where the biostatistician will be provided a masked dataset labeling the cohorts as Group 1, Group 2, and Group 3 without knowing their true clinical identities.
The clinical protocol follows a precise chronological order across all groups within standardized, visually isolated monitoring bays in the observation unit to minimize external noise and patient-to-patient cross-contamination. First, parents are thoroughly briefed on the trial framework, written informed voluntary consent is obtained, and the introductory information form is completed. Second, children undergo a brief cognitive triage assessing basic counting skills up to ten and size relations to ensure developmental compliance with the testing instruments, and patients in the active arms are given two to three minutes to physically touch and acclimate to the intervention devices to diminish initial novelty anxiety while the control group receives standard nebulizer mask orientation only. Third, baseline physiological parameters including heart rate and oxygen saturation are continuously recorded using a calibrated pediatric vital monitor equipped with a soft finger probe, respiratory rates are assessed manually via visual observation for a full 60 seconds, pre-procedure state anxiety is self-reported by the child using the state anxiety scale thermometer tool, and baseline procedural fear is measured utilizing a strict multi-evaluator triangulation method where the child, the accompanying parent, and the researcher independent of each other fill out the fear scale.
During the intra-procedural interventions, simultaneously with the emergency nurse initiating the standard nebulization therapy, the first intervention group utilizes an immersive, age-appropriate 360-degree panoramic underwater animation video launched via a smartphone inside the VR BOX headset with an adjustable head strap that accommodates the concurrent placement of the respiratory mask, allowing the child to actively navigate the digital marine environment via head movements. Simultaneously with the nebulization in the second intervention group, the researcher presents the patented laminated distraction cards set at the child's eye level, verbally engaging the child with structured, age-specific interactive riddles and visual search tasks printed on the back of the cards to ensure active cognitive load recruitment and prevent passive looking. The control group receives standard medical nebulization therapy administered by the clinical staff per emergency department routines without any external distraction tools or technological interventions. Immediately following the completion of the nebulization and mask removal, post-test evaluations are executed across all cohorts where vital signs are re-recorded, post-procedure state anxiety is self-scored by the child, and procedural fear is independently re-evaluated by the child, parent, and researcher, followed by the systematic sanitation of all non-disposable materials with medical-grade alcohol wipes between participants.
- Conditions
- Respiratory Tract Diseases, Pediatric Disorders, Anxiety, Fear
- Being tested
- Virtual Reality Goggles (VR BOX), Interactive Distraction Cards (DistrACTION® Cards), Standard Clinical Care
- Keywords
- Virtual Reality, Distraction Techniques, Inhalation Therapy, Procedural Anxiety, Fear, Pediatric Nursing, Randomized Controlled Trial
- Medical subject headings
- Respiratory Tract Diseases, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Virtual Reality Goggles (VR BOX)Device
Also called VR BOX, Virtual Reality Headset, 3D VR Glasses
Active cognitive distraction using a calibrated VR BOX headset equipped with 42mm aspheric optical resin lenses tailored to the child's interpupillary distance. Concurrently with standard medical nebulization, children watch an open-access 360-degree panoramic underwater world animation simulation video on a secure smartphone. The adjustable head strap allows concurrent mask placement. Duration matches the complete medical inhalation cycle (5-10 minutes), delivered in a single session. Clinical fear (CFS), state anxiety (CAS-S), and autonomically-driven physiology-specifically heart rate (HR), manual 60-second respiratory rate (RR), and oxygen saturation (SpO2)-are explicitly recorded at standardized pre-test (baseline) and post-test timelines immediately surrounding mask removal.
Interactive Distraction Cards (DistrACTION® Cards)Behavioural
Also called Pain Care Labs Distraction Cards
Interactive cognitive distraction using the patent-protected, liquid-impermeable laminated Pain Care Labs DistrACTION® Cards set held at the patient's exact eye level. Concurrently with standard emergency nebulization, the primary researcher verbally guides the child through structured, multi-layered visual illustrations and age-specific tasks (riddles, counting, find-and-search missions) printed on the reverse side to systematically capture working memory. Distraction lasts the entire inhalation cycle (5-10 minutes) in a single session. Clinical fear (CFS), state anxiety (CAS-S), and autonomically-driven physiology-specifically heart rate (HR), manual 60-second respiratory rate (RR), and oxygen saturation (SpO2)-are recorded at identical pre-test and post-test timelines.
Standard Clinical CareOther
Also called Routine Nebulization Therapy, Standard Hospital Care
Standard liquid aerosol emergency medical nebulization therapy administered by the unit clinical nursing staff according to routine hospital department guidelines and physician orders. The non-invasive mask delivery procedure is conducted entirely devoid of any supplementary non-pharmacological distraction materials, interactive cards, play-based therapies, or technological instruments, while maintaining regular parental presence at the bedside. To ensure comparative control, clinical fear (CFS), state anxiety (CAS-S), and physiological vital signs-specifically heart rate (HR), manual 60-second respiratory rate (RR), and oxygen saturation (SpO2)-are tracked at identical timelines.
| Study group | Role | What they receive |
|---|---|---|
| Virtual Reality Group | Experimental | In the virtual reality application, the researcher introduced the VR BOX goggles to the children before starting the inhaler therapy and allowed a 2 to 3-minute familiarization window. Concurrently with the initiation of the standard nebulization process, an age-appropriate 360-degree panoramic underwater world animation video was started inside the headset. This active distraction phase lasted for the entire duration of the inhalation therapy (approximately 5 to 10 minutes). The child actively explored the digital marine environment via head movements while breathing smoothly. The Children's Fear Scale (CFS), the Children's Anxiety Scale-State (CAS-S), and vital physiological parameters-specifically heart rate (HR), respiratory rate (RR), and peripheral oxygen saturation (SpO2)-were continuously monitored, evaluated, and recorded immediately before starting the therapy (baseline pre-test) and immediately after the final mask removal (post-test). Receives: Device: Virtual Reality Goggles (VR BOX) |
| Distraction Cards Group | Experimental | In the distraction cards group, the researcher introduced the laminated interactive Pain Care Labs DistrACTION® Cards to the children before inhaler therapy. At the start of nebulization, the cards were presented at the child's eye level and used throughout the 5-10-minute inhalation period. The researcher maintained the child's attention through age-appropriate riddles, character identification, and search-and-find activities on the cards. The Children's Fear Scale (CFS), Children's Anxiety Scale-State (CAS-S), and physiological parameters, including heart rate (HR), respiratory rate (RR), and peripheral oxygen saturation (SpO₂), were assessed immediately before therapy and after mask removal. Receives: Behavioral: Interactive Distraction Cards (DistrACTION® Cards) |
| Control Group | Other | In the control group, pediatric patients received the physician-prescribed standard emergency nebulization therapy administered by the unit clinical staff according to routine hospital protocols, entirely devoid of any supplementary non-pharmacological distraction materials, technology, interactive play cards, or games during the therapy. Children underwent the inhalation procedure accompanied by their parents. The Children's Fear Scale (CFS), the Children's Anxiety Scale-State (CAS-S), and vital physiological parameters-specifically heart rate (HR), respiratory rate (RR), and peripheral oxygen saturation (SpO2)-were evaluated, measured, and recorded at identical timelines, immediately before starting the therapy (baseline pre-test) and immediately after the final mask removal (post-test). Receives: Other: Standard Clinical Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
State Anxiety Levels
Self-reported by the child using the Children's Anxiety Scale-State (CAS-S) visual thermometer instrument. The scores range from 0 (not anxious/nervous at all) to 10 (very highly anxious/nervous), where higher scores reflect elevated state anxiety linked to the medical procedure.
Measured: Baseline (pre-procedure) and immediately after the final mask removal (post-procedure) [approximately 5-10 minutes apart]
Procedural Fear Levels
Evaluated using the Children's Fear Scale (CFS) through a triangulation method combining independent observations from the child, parent, and the researcher. The scale consists of 5 facial icons scored from 0 (no fear) to 4 (extreme fear), where higher scores indicate higher levels of procedural fear.
Measured: Baseline (pre-procedure) and immediately after the final mask removal (post-procedure) [approximately 5-10 minutes apart]
Secondary outcomes (3)
Heart Rate
Measured continuously using a calibrated Biolight V9 pediatric vital signs monitor with a soft finger probe to track autonomically-driven physiological stress responses. Recorded in beats per minute (bpm).
Measured: Baseline (pre-procedure) and immediately after the final mask removal (post-procedure) [approximately 5-10 minutes apart]
Peripheral Oxygen Saturation (SpO2)
Measured using a calibrated Biolight V9 pediatric vital signs monitor pulse oximetry probe to track respiratory ventilation quality and oxygenation tracking. Recorded as a percentage (%).
Measured: Baseline (pre-procedure) and immediately after the final mask removal (post-procedure) [approximately 5-10 minutes apart]
Respiratory Rate
Assessed manually via direct visual observation of chest and abdominal wall excursions by the primary researcher using a stopwatch for a full 60 seconds to evaluate stabilization of the breathing pattern. Recorded as breaths per minute.
Measured: Baseline (pre-procedure) and immediately after the final mask removal (post-procedure) [approximately 5-10 minutes apart]
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2026
- Study start28 Sep 2025
- Primary completionOct 2026 (estimated)
- Study completionOct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Respiratory Tract DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A parallel-group, three-arm randomized controlled clinical trial design. Participants are allocated into three independent parallel groups based on a stratified block randomization method by gender: Intervention Group 1 receives immersive virtual reality goggles, Intervention Group 2 receives interactive distraction cards, and the Control Group receives standard emergency medical nebulization therapy.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bandırma Onyedi Eylül University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ecem Bakış, Bandırma Onyedi Eylül University
- Investigators
- Diler Yılmaz, Prof. Dr., Study chair, Bandırma Onyedi Eylül University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07780331
- Sponsor's protocol ID
- 2025-124
- Status last verified
- Aug 2026
- First submitted
- 19 Aug 2026
- Last updated
- 21 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared with external researchers in order to protect patient privacy and comply with national institutional ethical committee protocols regarding pediatric participant confidentiality.
Publications
Canbulat N, Inal S, Sonmezer H. Efficacy of distraction methods on procedural pain and anxiety by applying distraction cards and kaleidoscope in children. Asian Nurs Res (Korean Soc Nurs Sci). 2014 Mar;8(1):23-8. doi: 10.1016/j.anr.2013.12.001. Epub 2013 Dec 14.
PubMed 25030489Durak H, Uysal G. The Effect of Cartoon Watching and Distraction Card on Physiologic Parameters and Fear Levels During Inhalation Therapy in Children: A Randomized Controlled Study. J Trop Pediatr. 2021 Jan 29;67(1):fmab018. doi: 10.1093/tropej/fmab018.
PubMed 33742204Eijlers R, Utens EMWJ, Staals LM, de Nijs PFA, Berghmans JM, Wijnen RMH, Hillegers MHJ, Dierckx B, Legerstee JS. Systematic Review and Meta-analysis of Virtual Reality in Pediatrics: Effects on Pain and Anxiety. Anesth Analg. 2019 Nov;129(5):1344-1353. doi: 10.1213/ANE.0000000000004165.
PubMed 31136330
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Using Virtual Reality Glasses and Gaming Cards on Fear, Anxiety, and Physiological Parameters in Children Administered Inhaler Medication
- ClinicalTrials.gov ID
- NCT07780331
- Acronym / sponsor ID
- 2025-124
- Conditions
- Respiratory Tract Diseases, Pediatric Disorders, Anxiety, Fear
- Keywords
- Virtual Reality, Distraction Techniques, Inhalation Therapy, Procedural Anxiety, Fear, Pediatric Nursing, Randomized Controlled Trial
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Bandırma Onyedi Eylül UniversityUniversity, hospital or other
- Study start
- 28 Sep 2025 (actual)
- Primary completion
- Oct 2026 (estimated)
- Study completion
- Oct 2026 (estimated)
- First posted
- 21 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the effects of using virtual reality headsets and play cards during the administration of inhaler medication in pediatric patients. The primary goal is to determine how these distraction methods influence children's fear, anxiety levels, and physiological parameters (such as heart rate and oxygen saturation). The study population consists of pediatric patients aged between 4 and 6 years. Data collection for the targeted sample size of 150 children commenced in September, and the recruitment process is currently ongoing.Children receiving inhaler treatments often experience fear and anxiety, which can negatively affect their treatment compliance and vital signs. In this study, participants are divided into different groups to compare the effectiveness of virtual reality headsets and traditional play cards as distraction tools.
Detailed description
This single-blind, parallel-group, randomized controlled clinical trial is designed to evaluate and compare the efficacy of two distinct cognitive distraction techniques, namely virtual reality goggles and interactive distraction cards, against a standard care control group on fear, anxiety, and vital physiological parameters in pediatric patients aged four to six years requiring inhaler medication within an emergency department setting. The study is actively being conducted at the Emergency Department of Susurluk State Hospital, having commenced in September 2025. The target sample size was rigorously calculated using G*Power software based on a standard effect size of 0.25, a significance level of 0.05, and a statistical power of 0.90 for a mixed-design repeated measures analysis of variance, determining a minimum required sample size of 45 participants per group. To account for potential data loss or attrition during the ongoing clinical process, the sample size was increased by approximately ten percent, aiming to recruit a total of 150 pediatric patients equally distributed with 50 participants in each of the three study arms.
To eliminate selection bias and ensure an equal distribution of demographic factors, a stratified block randomization method based on gender is utilized. An online randomizer program is managed by an independent faculty member not involved in the research team to generate two separate randomization sequences for female and male children with variable block sizes of three and six to ensure balanced allocations across the arms. Sequential protocol numbers corresponding to the gender-specific lists are kept completely concealed from the primary researcher until immediately prior to the clinical intervention. While researcher blinding is impossible due to the nature of administering the interventions, a strict single-blind protocol is maintained for data analysis where the biostatistician will be provided a masked dataset labeling the cohorts as Group 1, Group 2, and Group 3 without knowing their true clinical identities.
The clinical protocol follows a precise chronological order across all groups within standardized, visually isolated monitoring bays in the observation unit to minimize external noise and patient-to-patient cross-contamination. First, parents are thoroughly briefed on the trial framework, written informed voluntary consent is obtained, and the introductory information form is completed. Second, children undergo a brief cognitive triage assessing basic counting skills up to ten and size relations to ensure developmental compliance with the testing instruments, and patients in the active arms are given two to three minutes to physically touch and acclimate to the intervention devices to diminish initial novelty anxiety while the control group receives standard nebulizer mask orientation only. Third, baseline physiological parameters including heart rate and oxygen saturation are continuously recorded using a calibrated pediatric vital monitor equipped with a soft finger probe, respiratory rates are assessed manually via visual observation for a full 60 seconds, pre-procedure state anxiety is self-reported by the child using the state anxiety scale thermometer tool, and baseline procedural fear is measured utilizing a strict multi-evaluator triangulation method where the child, the accompanying parent, and the researcher independent of each other fill out the fear scale.
During the intra-procedural interventions, simultaneously with the emergency nurse initiating the standard nebulization therapy, the first intervention group utilizes an immersive, age-appropriate 360-degree panoramic underwater animation video launched via a smartphone inside the VR BOX headset with an adjustable head strap that accommodates the concurrent placement of the respiratory mask, allowing the child to actively navigate the digital marine environment via head movements. Simultaneously with the nebulization in the second intervention group, the researcher presents the patented laminated distraction cards set at the child's eye level, verbally engaging the child with structured, age-specific interactive riddles and visual search tasks printed on the back of the cards to ensure active cognitive load recruitment and prevent passive looking. The control group receives standard medical nebulization therapy administered by the clinical staff per emergency department routines without any external distraction tools or technological interventions. Immediately following the completion of the nebulization and mask removal, post-test evaluations are executed across all cohorts where vital signs are re-recorded, post-procedure state anxiety is self-scored by the child, and procedural fear is independently re-evaluated by the child, parent, and researcher, followed by the systematic sanitation of all non-disposable materials with medical-grade alcohol wipes between participants.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
- Model description
- A parallel-group, three-arm randomized controlled clinical trial design. Participants are allocated into three independent parallel groups based on a stratified block randomization method by gender: Intervention Group 1 receives immersive virtual reality goggles, Intervention Group 2 receives interactive distraction cards, and the Control Group receives standard emergency medical nebulization therapy.
| Arm | Type | Receives |
|---|---|---|
| Virtual Reality Group | Experimental | Device: Virtual Reality Goggles (VR BOX)In the virtual reality application, the researcher introduced the VR BOX goggles to the children before starting the inhaler therapy and allowed a 2 to 3-minute familiarization window. Concurrently with the initiation of the standard nebulization process, an age-appropriate 360-degree panoramic underwater world animation video was started inside the headset. This active distraction phase lasted for the entire duration of the inhalation therapy (approximately 5 to 10 minutes). The child actively explored the digital marine environment via head movements while breathing smoothly. The Children's Fear Scale (CFS), the Children's Anxiety Scale-State (CAS-S), and vital physiological parameters-specifically heart rate (HR), respiratory rate (RR), and peripheral oxygen saturation (SpO2)-were continuously monitored, evaluated, and recorded immediately before starting the therapy (baseline pre-test) and immediately after the final mask removal (post-test). |
| Distraction Cards Group | Experimental | Behavioral: Interactive Distraction Cards (DistrACTION® Cards)In the distraction cards group, the researcher introduced the laminated interactive Pain Care Labs DistrACTION® Cards to the children before inhaler therapy. At the start of nebulization, the cards were presented at the child's eye level and used throughout the 5-10-minute inhalation period. The researcher maintained the child's attention through age-appropriate riddles, character identification, and search-and-find activities on the cards. The Children's Fear Scale (CFS), Children's Anxiety Scale-State (CAS-S), and physiological parameters, including heart rate (HR), respiratory rate (RR), and peripheral oxygen saturation (SpO₂), were assessed immediately before therapy and after mask removal. |
| Control Group | Other | Other: Standard Clinical CareIn the control group, pediatric patients received the physician-prescribed standard emergency nebulization therapy administered by the unit clinical staff according to routine hospital protocols, entirely devoid of any supplementary non-pharmacological distraction materials, technology, interactive play cards, or games during the therapy. Children underwent the inhalation procedure accompanied by their parents. The Children's Fear Scale (CFS), the Children's Anxiety Scale-State (CAS-S), and vital physiological parameters-specifically heart rate (HR), respiratory rate (RR), and peripheral oxygen saturation (SpO2)-were evaluated, measured, and recorded at identical timelines, immediately before starting the therapy (baseline pre-test) and immediately after the final mask removal (post-test). |
Who may qualify
- Ages
- 4 to 6 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (8 listed)
- Child being between the ages of 4 and 6 years.
- Parents and children being completely voluntary to participate in the study.
- Child having no visual, auditory, or cognitive communication barriers.
- Child's cognitive level and motor development being appropriate for their age.
- Child having no life-threatening acute or chronic systemic disease.
Key exclusion criteria (3 listed)
- Child having any acute clinical condition that mechanically prevents inhaler treatment.
- Child having a severe, life-threatening acute or chronic health problem at presentation.
- Sudden development of severe clinical instability preventing completion of the trial.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Virtual Reality Goggles (VR BOX)Also: VR BOX, Virtual Reality Headset, 3D VR GlassesActive cognitive distraction using a calibrated VR BOX headset equipped with 42mm aspheric optical resin lenses tailored to the child's interpupillary distance. Concurrently with standard medical nebulization, children watch an open-access 360-degree panoramic underwater world animation simulation video on a secure smartphone. The adjustable head strap allows concurrent mask placement. Duration matches the complete medical inhalation cycle (5-10 minutes), delivered in a single session. Clinical fear (CFS), state anxiety (CAS-S), and autonomically-driven physiology-specifically heart rate (HR), manual 60-second respiratory rate (RR), and oxygen saturation (SpO2)-are explicitly recorded at standardized pre-test (baseline) and post-test timelines immediately surrounding mask removal. | Device | Virtual Reality Group |
| Interactive Distraction Cards (DistrACTION® Cards)Also: Pain Care Labs Distraction CardsInteractive cognitive distraction using the patent-protected, liquid-impermeable laminated Pain Care Labs DistrACTION® Cards set held at the patient's exact eye level. Concurrently with standard emergency nebulization, the primary researcher verbally guides the child through structured, multi-layered visual illustrations and age-specific tasks (riddles, counting, find-and-search missions) printed on the reverse side to systematically capture working memory. Distraction lasts the entire inhalation cycle (5-10 minutes) in a single session. Clinical fear (CFS), state anxiety (CAS-S), and autonomically-driven physiology-specifically heart rate (HR), manual 60-second respiratory rate (RR), and oxygen saturation (SpO2)-are recorded at identical pre-test and post-test timelines. | Behavioural | Distraction Cards Group |
| Standard Clinical CareAlso: Routine Nebulization Therapy, Standard Hospital CareStandard liquid aerosol emergency medical nebulization therapy administered by the unit clinical nursing staff according to routine hospital department guidelines and physician orders. The non-invasive mask delivery procedure is conducted entirely devoid of any supplementary non-pharmacological distraction materials, interactive cards, play-based therapies, or technological instruments, while maintaining regular parental presence at the bedside. To ensure comparative control, clinical fear (CFS), state anxiety (CAS-S), and physiological vital signs-specifically heart rate (HR), manual 60-second respiratory rate (RR), and oxygen saturation (SpO2)-are tracked at identical timelines. | Other | Control Group |
Primary outcome
State Anxiety Levels
Time frame: Baseline (pre-procedure) and immediately after the final mask removal (post-procedure) [approximately 5-10 minutes apart]
Self-reported by the child using the Children's Anxiety Scale-State (CAS-S) visual thermometer instrument. The scores range from 0 (not anxious/nervous at all) to 10 (very highly anxious/nervous), where higher scores reflect elevated state anxiety linked to the medical procedure.
Procedural Fear Levels
Time frame: Baseline (pre-procedure) and immediately after the final mask removal (post-procedure) [approximately 5-10 minutes apart]
Evaluated using the Children's Fear Scale (CFS) through a triangulation method combining independent observations from the child, parent, and the researcher. The scale consists of 5 facial icons scored from 0 (no fear) to 4 (extreme fear), where higher scores indicate higher levels of procedural fear.
3 secondary outcomes
Heart Rate
Time frame: Baseline (pre-procedure) and immediately after the final mask removal (post-procedure) [approximately 5-10 minutes apart]
Peripheral Oxygen Saturation (SpO2)
Time frame: Baseline (pre-procedure) and immediately after the final mask removal (post-procedure) [approximately 5-10 minutes apart]
Respiratory Rate
Time frame: Baseline (pre-procedure) and immediately after the final mask removal (post-procedure) [approximately 5-10 minutes apart]
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2026.
- Background: PubMed 25030489Canbulat N, Inal S, Sonmezer H. Efficacy of distraction methods on procedural pain and anxiety by applying distraction cards and kaleidoscope in children. Asian Nurs Res (Korean Soc Nurs Sci). 2014 Mar;8(1):23-8. doi: 10.1016/j.anr.2013.12.001. Epub 2013 Dec 14.
- Background: PubMed 33742204Durak H, Uysal G. The Effect of Cartoon Watching and Distraction Card on Physiologic Parameters and Fear Levels During Inhalation Therapy in Children: A Randomized Controlled Study. J Trop Pediatr. 2021 Jan 29;67(1):fmab018. doi: 10.1093/tropej/fmab018.
- Background: PubMed 31136330Eijlers R, Utens EMWJ, Staals LM, de Nijs PFA, Berghmans JM, Wijnen RMH, Hillegers MHJ, Dierckx B, Legerstee JS. Systematic Review and Meta-analysis of Virtual Reality in Pediatrics: Effects on Pain and Anxiety. Anesth Analg. 2019 Nov;129(5):1344-1353. doi: 10.1213/ANE.0000000000004165.
- Official YouTube link for the 360-degree panoramic underwater animation video used as the active distraction stimulus in the Virtual Reality Group.Link provided by the sponsor.
- Official web page of Pain Care Labs demonstrating the structural and pedagogical properties of the original DistrACTION® Cards used in the study.Link provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant data will not be shared with external researchers in order to protect patient privacy and comply with national institutional ethical committee protocols regarding pediatric participant confidentiality.
Related trials for Respiratory Tract Diseases
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Diler Yılmaz, Prof. Dr. contact
Diler Yılmaz, Prof. Dr. study chair
Bandırma Onyedi Eylül University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Virtual Reality Goggles (VR BOX), Interactive Distraction Cards (DistrACTION® Cards) and Standard Clinical Care in people with Respiratory Tract Diseases and Pediatric Disorders, run by Bandırma Onyedi Eylül University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ecem Bakış, BSc, RN (+90 5459355068, bakisecem0@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
State Anxiety Levels (time frame: Baseline (pre-procedure) and immediately after the final mask removal (post-procedure) [approximately 5-10 minutes apart]). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07780331, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026.